Christopher Morabito
Company: Astria Therapeutics
Job title: Chief Medical Officer
Seminars:
Track Chair: 10:13 am
day: Day Two Discovery Track AM
STAR-0310: A Monoclonal Antibody OX40 Antagonist 12:15 pm
OX40 inhibition is a clinically validated mechanism for the treatment of AD Using half-life extension technology with the aim of durable efficacy with less frequent dosing every 2-3 months, STAR0310 is designed with the potential to be a first-choice treatment that reduces disease and treatment burden to help normalize the lives of people with atopic dermatitis STAR-0310 has a…Read more
day: Day One Discovery Track AM
Bridging the Gap: Translating Candidates to the Clinic for Chronic Disease 10:15 am
day: Day Two Discovery Track AM